Early remdesivir to prevent severe COVID-19 in recipients of solid organ transplant: a real-life study from Northern Italy
Int. j. infect. dis; 121 (), 2022
The effectiveness of a 3-day course of remdesivir to prevent severe disease in patients with
COVID-19 who received solid organ transplant (SOT) is unknown. We wanted to study the efficacy of this
therapeutic option in patients with COVID-19 who received SOT in preventing both hospitalizations for
outpati...